Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Nymox reports data from pivotal trial of NX-1207

July 15, 2013

ProMetic set to advance lead antifibrotic drug candidate PBI-4050 to clinic

July 12, 2013

CRUISE-1 phase III trial of iron-delivery drug SFP meets primary endpoint

July 12, 2013

La Jolla Pharmaceutical begins dosing in phase II trial of GCS-100 in chronic kidney disease

July 9, 2013

Pharmaxis and University of Sydney receive Australian Research Council grants

July 8, 2013

Phase II trial of AQX-1125 in interstitial cystitis/bladder pain syndrome is under way

July 8, 2013

Vivus obtains European approval for avanafil

June 27, 2013

Mesoblast receives approval for trial of mesenchymal precursor cells

June 27, 2013

Anthera Pharmaceuticals begins phase II BRIGHT-SC study in IgA nephropathy

June 26, 2013

Vivus study shows avanafil is effective for sexual activity within 15 minutes

June 21, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...